695 results about "Antibody detection" patented technology

The invention discloses an antibody for resisting HPV16 type E6 protein and E7 protein, a detection product and application of the antibody and the detection product, and relates to the technical field of monoclonal antibodies. The antibody comprises a heavy chain complementarity determining region in a heavy chain variable region as shown in SEQ ID NO: 1 and a light chain complementarity determining region in a light chain variable region as shown in SEQ ID NO: 2. The antibody can be specifically combined with HPV16 E6 protein and E7 protein, and a detection product for detecting the HPV16 E6 / E7 antigen can be developed based on the antibody provided by the invention. Tests show that a kit developed based on the monoclonal antibody has the advantages of high detection sensitivity, rapidness and strong tolerance on the HPV16 E6 / E7 antigen, can be used for quality control in the production process of the recombinant human HPV16 E6 / E7 antigen, and can efficiently and accurately quantify the antigen content in a vaccine and monitor the quality of the vaccine.

The invention relates to a magnetic particle capable of being specifically combined with an anti-Nephrin antibody in a sample. The magnetic particle comprises a magnetic bead which can be specifically combined with an anti-Nephrin autoantibody of a mammal and is coated with a polypeptide or a fragment of the polypeptide; wherein the magnetic beads are carboxyl magnetic beads; the particle size of the carboxyl magnetic beads is 1-5 [mu] m; preferably, the particle size of the carboxyl magnetic beads is 1-3 [mu] m; more preferably, the particle size of the magnetic beads is 3 microns. The anti-Nephrin antibody detection method disclosed by the invention is short in detection time, high in sensitivity, strong in specificity, stable and reliable in result, high in uniformity and easy to clinically popularize.

The invention discloses an anti-interleukin-6 antibody or a reagent and a kit for detecting interleukin-6, and relates to the field of antibodies. The anti-interleukin-6 antibody disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, provides an important raw material source for detection of interleukin-6, and has good affinity or activity.

The invention relates to a kit for detecting a myasthenia gravis antibody and a preparation method of the kit. The kit for detecting the myasthenia gravis antibody comprises the following components: a myasthenia gravis antibody detection plate, a working solution, PBS (Phosphate Buffer Solution), a fluorescent secondary antibody and a mounting medium, wherein the myasthenia gravis antibody detection plate is prepared by mixing hela cells containing MUSK, LRP4, Titin and RYR1 proteins with modified polystyrene and then spotting the mixture on a glass slide; the modified polystyrene is obtained by reacting chloromethyl polystyrene resin with dopamine. According to the present invention, the existence of the four antibodies such as MUSK, LRP4, Titin and RYR1 can be simultaneously detected in the same system. The multiple detection mode can comprehensively reflect the antibody spectrum of the myasthenia gravis patient, reduce the sample size and the detection time, reduce the detection cost, and improve the detection efficiency and the clinical application value.

The invention belongs to the technical field of immunology and in vitro diagnosis, and relates to a monoclonal antibody aiming at bovine nodular skin disease virus (LSDV) L1R protein. According to the invention, the LSDV recombinant L1R protein with deletion of a transmembrane region (182-204aa) is obtained through expression; after a mouse is immunized by the protein, a monoclonal antibody 8D5 which is good in reactivity and specificity and aims at the LSDV L1R protein is screened out; heavy chain and light chain variable region sequences for coding the monoclonal antibody 8D5 are obtained; the monoclonal antibody 8D5 can be subjected to specific reaction with LSDV L1R protein, the recombinant protein L1R can be specifically recognized by bovine LSDV positive serum, meanwhile, the monoclonal antibody 8D5 can be used for establishing an LSDV ELISA antibody detection method, and a foundation is laid for LSDV diagnostic technology and vaccine research and development.

The invention relates to a detection kit for an autoimmune encephalitis antibody and a preparation method of the detection kit. The detection kit for the antibody against myasthenia gravis comprises the following components: a myasthenia gravis antibody detection plate, a working solution, PBS (Phosphate Buffer Solution), a fluorescent secondary antibody and a mounting medium. According to the technical scheme, the carboxymethyl cellulose modified trehalose is used as the carrier of the antibody detection material to adsorb and wrap the cells, so that the fixing efficiency and stability of the cells on the detection carrier are remarkably improved, and the biological activity maintaining capability of the cells is enhanced, thereby improving the sensitivity and specificity of antibody detection and further improving the detection accuracy of the antibody. The carboxymethyl cellulose modified trehalose also can provide good biocompatibility, has excellent surface stability, can maintain the natural conformation and function of cells in the detection process, and effectively reduces the detection error caused by antigen denaturation or degradation.

The invention belongs to the technical field of medicines, and particularly relates to application of circRNA (Ribonucleic Acid) coded protein as a gastric cancer marker. The circRNA disclosed by the invention is provided with an ORF (Open Reading Frame) capable of coding a microprotein circUBE2G1-99aa of 99 amino acids, and the amino acid sequence of the protein is shown as SEQ ID NO: 1. According to the present invention, the designed circUBE2G1-99aa targeting antibody is adopted to detect the expression level of circUBE2G1-99aa in the collected clinical sample, and the expression level of circUBE2G1-99aa in the stomach cancer patient tissue is down-regulated, and is negatively correlated with the large tumor, the lymph node metastasis and the advanced pathological stage of the stomach cancer patient.

The application belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody pair for detecting feline immunodeficiency virus p24 protein and application thereof. The monoclonal antibody pair is monoclonal antibody 1D8 and monoclonal antibody 1H10, which can specifically recognize feline immunodeficiency virus p24 protein, and the heavy chain and light chain variable region complementarity determining region sequences of 1D8 and 1H10 are clear, and are respectively shown as SEQ ID NO. 1-12. The antibody pair can effectively avoid cross reaction, and significantly improve the accuracy and sensitivity of detection; the colloidal gold detection test strip constructed based on the antibody pair is simple and fast in operation, is suitable for early antigen detection of FIV infection, solves the problem that existing antibody detection cannot distinguish natural infection and vaccine immunization, and provides a reliable technical means for on-site screening and disease prevention and control of FIV.

The invention discloses a novel coronavirus neutralizing antibody, a detection kit and application of the novel coronavirus neutralizing antibody. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR12 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR12 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR12 to S-Trimer and RBD under 2-fold and 300-fold dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR12 has high affinity and dilution stability and is suitable for clinical large-dose administration.

The invention relates to an antibody detection kit for neuroparatoma syndrome and a preparation method of the antibody detection kit. The antibody detection kit for neuroparatoma syndrome comprises an antibody detection strip, a cleaning solution, a buffer solution and an auxiliary agent, wherein the antibody detection strip is a nitrocellulose membrane which is coated with antigen proteins containing Amphiphysin, CV2, GAD65, Hu, PNMA2 (Ma2 / Ta), Recovery, Ri, SOX1, Titin, Tr (DNER), Yo and Zic4. The invention further discloses a detection method of the antibody detection strip. The antibody detection kit disclosed by the invention can be used for simultaneously detecting 12 autoantibodies related to the neuroparatoma syndrome. The design of simultaneous detection of multiple antibodies greatly improves the comprehensiveness of detection, so that multiple possible pathogenic factors can be covered in single detection, the kit can be used for differential diagnosis of suspected neuroparatoma syndrome patients in professional laboratories, and the problem of missed diagnosis caused by single antibody detection is avoided.

The invention provides an anti-beta2-glycoprotein I antibody detection reagent and a chemiluminescence detection kit, and the anti-beta2-glycoprotein I antibody detection reagent comprises a biotin-labeled beta2-glycoprotein I antigen prepared by reacting biotin connected with an LPETG label with the beta2-glycoprotein I antigen under the catalytic action of Sortase A enzyme. The N terminal of the beta2-glycoprotein I antigen is labeled with the biotin with a specific label in a fixed point manner, all amino acid sequence regions (structural domains I-V) of the beta2-glycoprotein I antigen are not influenced, and meanwhile, the purity of a connection product is high, the difference between batches is small, and the method is suitable for large-scale production. The positive detection rate and the detection result accuracy of the anti-beta2-glycoprotein I antibody magnetic particle chemiluminescence detection kit can be improved, and the difference between batches can be reduced.

The invention relates to the technical fields of gene engineering, antibody engineering and immunodiagnosis. The invention provides a recombinant humanized anti-Cpn IgM monoclonal antibody. The monoclonal antibody comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprises three complementary determining regions CDR1, CDR2 and CDR3, and the amino acid sequences of the three complementary determining regions are respectively shown as SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5; the heavy chain variable region comprises three complementary determining regions CDR1, CDR2 and CDR3, and the amino acid sequences of the three complementary determining regions are shown as SEQ ID NO.6, SEQ ID NO.7 and SEQ ID NO.8 respectively. The invention also provides a method for preparing the monoclonal antibody. The recombinant humanized anti-Cpn IgM monoclonal antibody provided by the invention is expressed in mammalian cells by utilizing a gene recombination technology, has the characteristics of high purity, small batch difference and the like, and can be applied to a Cpn IgM antibody detection kit as a quality control product; as a quality control product, the recombinant humanized anti-Cpn IgM monoclonal antibody has the advantages of high sensitivity, high safety, inter-batch stability and the like.

The invention discloses a novel coronavirus neutralizing antibody, a detection kit and application of the novel coronavirus neutralizing antibody. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR75 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR75 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR75 to S-Trimer and RBD under 2-fold and 300-fold dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR75 has high affinity and dilution stability and is suitable for clinical large-dose administration.

The invention discloses a novel coronavirus neutralizing antibody GR46, a detection kit and application of the novel coronavirus neutralizing antibody GR46. The amino acid sequence of a heavy chain variable region of the neutralizing antibody is shown as SEQ ID No.1, and the amino acid sequence of a light chain variable region of the neutralizing antibody is shown as SEQ ID No.2. The antibody with mature affinity is screened through bioinformatics analysis of a single B cell, the antibody screening process is optimized by combining single cell RNA sequencing, VDJ rearrangement analysis and somatic cell hypermutation research, blindness of a traditional method is avoided, and the accuracy and effectiveness of antibody screening are improved. According to the neutralizing antibody GR46 provided by the invention, a heavy chain variable region and a light chain variable region of the neutralizing antibody GR46 can be specifically combined with an RBD structural domain of the SARS-CoV-2 and an S-Trimer structural domain of an Omicro variant, so that a broad-spectrum neutralizing effect on the SARS-CoV-2 virus and the variant thereof is realized. The binding activity of the antibody GR46 to S-Trimer and RBD under 2-time and 300-time dilution conditions is obviously superior to that of other antibodies, which indicates that the antibody GR46 has high affinity and dilution stability and is suitable for clinical large-dose administration.

The invention provides a characteristic protein of serotype I chicken Marek's disease virus and detection application, and belongs to the technical field of virus detection. The invention provides a recombinant gene derived from serum I type chicken Marek's disease virus. The nucleotide sequence of the recombinant gene is shown as SEQ ID No. 1. The recombinant gene disclosed by the invention is used for coding the MDV-1 recombinant PP38 protein, and the MDV-1 recombinant PP38 protein can be applied to enzyme-linked immuno sorbent assay (ELISA) detection. The invention also provides an ELISA detection kit constructed by using the MDV-1 recombinant PP38 protein, and the ELISA detection kit can be used for clinical MDV-1 serum antibody detection, SPF chicken screening, exogenous virus antibody detection of poultry live vaccines or virus seeds, epidemiological investigation and the like, so as to prevent and control transmission of MDV-1 infection.

The invention belongs to the technical field of biology, and relates to a latex immunochromatography test strip for rapidly detecting porcine epidemic diarrhea virus (PEDV) and a preparation method of the latex immunochromatography test strip. The test strip comprises a PVC (polyvinyl chloride) bottom plate, a sample pad, a combination pad, a nitrocellulose membrane and a water absorption pad, a quality control line C and a detection line T are arranged on the nitrocellulose membrane. A latex microsphere labeled PEDV N protein monoclonal capture antibody is sprayed on the combination pad, a detection line T is coated with a PEDV N protein monoclonal detection antibody 1E1, and a quality control line C is coated with goat anti-mouse IgG. The test strip can specifically recognize PEDV, and does not react with other porcine intestinal coronaviruses with similar clinical symptoms. The test strip is good in specificity, relatively high in sensitivity and simple to operate, a result is interpreted within 10 minutes, and compared with a traditional colloidal gold detection technology, the stability and the color development effect are obviously improved.

The invention discloses a porcine delta coronavirus monoclonal antibody and application thereof in preparation of an antigen detection test strip. The detection test strip comprises a polyvinyl chloride bottom plate on the lowest layer, and a sample pad, a conjugate pad, a nitrocellulose membrane and a water absorption pad are sequentially laid on the polyvinyl chloride bottom plate in the flowing direction; the sample pad is partially overlapped on the combination pad, and the combination pad and the water absorption pad are respectively overlapped on two sides of the nitrocellulose membrane; a detection line and a quality control line are arranged on the nitrocellulose membrane along the flowing direction; an antibody marked by red latex microspheres is sprayed on the combination pad, a coated antibody is sprayed on the detection line, and coated commercial goat anti-mouse IgG is sprayed on the quality control line. The test strip adopts a double-antibody sandwich method for detection, and has the advantages of high detection speed, high sensitivity, strong specificity and the like. The detection result is visual, clear and easy to interpret; the detection process does not need any instrument and equipment, operators do not need professional training, operation is easy and convenient, and the method is particularly suitable for on-site rapid diagnosis.

The invention belongs to the technical field of biological detection, and particularly relates to a monoclonal antibody pair for detecting cat immunodeficiency virus p24 protein and application of the monoclonal antibody pair. The monoclonal antibody pair is a monoclonal antibody 1D8 and a monoclonal antibody 1H10 and can specifically recognize cat immunodeficiency virus p24 protein, and sequences of complementary determining regions of variable regions of a heavy chain and a light chain of the 1D8 and the 1H10 are clear and are respectively shown as SEQ ID NO.1-12. The antibody pair can effectively avoid cross reaction, and the accuracy and sensitivity of detection are remarkably improved; the colloidal gold test strip constructed on the basis of the antibody pair is simple, convenient and rapid to operate, is suitable for early antigen detection of FIV infection, solves the problem that natural infection and vaccine immunity cannot be distinguished in existing antibody detection, and provides a reliable technical means for FIV field screening and disease prevention and control.

The invention relates to the technical field of antibodies, in particular to an anti-African swine fever virus p30 protein monoclonal antibody and application thereof, and the anti-African swine fever virus p30 protein monoclonal antibody can be specifically combined with African swine fever virus p30 protein. The anti-ASFV p30 protein monoclonal antibody is prepared by immunizing a BALB / c mouse through an immunological method, and the antibody is high in specificity, titer and affinity and can be applied to immunological detection or antibody detection kits.

The invention relates to the technical field of antibody detection methods, in particular to a diagnosis method and a detection system based on autoimmune disease antibody detection, and the method comprises the following steps: S1, an analysis module obtains electrochemistry related information and light reflection related information through electrochemical analysis and light reflection analysis; related information of electrochemistry and related information of light reflection are transmitted to the control module; s2, the control module obtains an antibody concentration index according to the electrochemistry related information and the light reflection related information, and transmits the antibody concentration index to a diagnosis module; s3, the diagnosis module obtains strong or weak immunoreaction information according to the antibody concentration index, and transmits the strong or weak immunoreaction information to the communication module; and S4, the communication module transmits strong or weak immunoreaction information to the user side. Immunoassay is combined with electrochemical analysis and light reflection analysis for detection, and the accuracy and comprehensiveness of detection can be improved by analyzing in different directions and combining results.

The invention discloses an antibody for detecting indol sulfate, a detection kit and application of the antibody, and the antibody can be specifically combined with indol sulfate and has high combination activity. The detection kit detects the content of indoxyl sulfate in a to-be-detected sample through a competitive binding reaction of an immunomagnetic bead coated indoxyl sulfate antibody, an antigen in the sample and an alkaline phosphatase labeled indoxyl sulfate antigen, and has important economic value and social significance.

The invention relates to a biotechnology, and particularly discloses a soluble fibrous protein (SF) antibody and an application of the soluble fibrous protein antibody. According to the present invention, the single B cell antibody preparation technology and the flow cytometry sorting method are firstly applied to the blood coagulation in vitro diagnosis fibrinolysis system detection antibody development, and the mammalian cell expression system (293F) is adopted to successfully express and obtain the three strains of the SF monoclonal antibodies (the antibody numbers are SF-1, SF-2 and SF-3) with the biological activity; the three antibodies have specific reactions with SF, have no cross reactions with primary fibrinolytic substances (X, Y and D), can be applied to the fields of SF indirect ELISA and Western blotting detection and screening, make up the vacancy of domestic SF antibodies in the market, and realize fibrinolytic system detection integrity.

The invention discloses a specific monoclonal antibody for resisting a Nipah virus Post-F protein, the monoclonal antibody comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, and the light chain variable region comprises LCDR1, LCDR2 and LCDR3; wherein the HCDR1, the HCDR2 and the HCDR3 respectively comprise the HCDR1, the HCDR2 and the HCDR3 in a heavy chain variable region of which the amino acid sequence is any one of SEQ ID NO: 4, 13, 20, 25, 30, 34 or 42, or respectively have at least 85% sequence identity with the HCDR1, the HCDR2 and the HCDR3; and / or the LCDR1, the LCDR2 and the LCDR3 respectively comprise LCDR1, LCDR2 and LCDR3 in a light chain variable region with the amino acid sequence of any one of SEQ ID NO: 9, 16, 23, 28, 32, 37 or 46, or respectively have at least 85% sequence identity with the LCDR1, the LCDR2 and the LCDR3. The anti-Nipah virus Post-F protein monoclonal antibody disclosed by the invention can be specifically combined with a Post-F conformation protein, and has the application potential of being developed into a Nipah virus antibody detection kit or a virus neutralizing antibody drug.

The invention discloses a monoclonal antibody, a hybridoma cell secreting the monoclonal antibody and application of the hybridoma cell, and belongs to the field of peptides. The invention aims to provide a monoclonal antibody and a hybridoma cell secreting the monoclonal antibody. The hybridoma cell secreting the monoclonal antibody disclosed by the invention is a hybridoma cell 3G3, and the preservation number of the hybridoma cell 3G3 in the China General Microbiological Culture Collection Center (CGMCC) is CGMCC No.46345. The monoclonal antibody and the BVDV antibody detection kit based on the monoclonal antibody and the blocking ELISA method can be used for detecting a neutralizing antibody of the BVDV, and have the characteristics of strong specificity, good sensitivity, high sensitivity, high accuracy and the like.

The invention discloses a lateral flow chromatography test strip for detecting perfluorooctanoic acid by combining gold nanoparticles, a nucleic acid aptamer and an antibody. According to the test strip, a nucleic acid aptamer marked by gold nanoparticles is combined with PFOA molecules to form a nucleic acid aptamer with a G-quadruplex structure, and then the nucleic acid aptamer with the G-quadruplex structure is specifically recognized and captured by an anti-BG4 antibody, so that specific visual detection of perfluorooctanoic acid is realized. After a sample is injected, a G-quadruplex structure formed by the PFOA and the nucleic acid aptamer acts with the anti-BG4 antibody coated on the test strip, so that the gold nanoparticles are agglomerated to generate a chromogenic reaction, the signal intensity can be detected by naked eyes or reading equipment, the visual detection limit is 10 mu M, and the equipment detection limit is 304 nM. The test strip has the advantages of high detection speed, high specificity and high sensitivity, and is suitable for field detection and rapid screening. Compared with a traditional method, the method realizes simple, convenient and economical detection of PFOA, and has a wide application prospect.

The present invention relates to an ELISA antibody detection method for serotype 2 Riemerella anatipestifer and an application thereof. The method is based on a bacterial lipopolysaccharide coated plate, and an indirect ELISA method for serotype 2 Riemerella anatipestifer is established through optimization of optimal reaction conditions, determination of critical values, specificity tests, sensitivity tests, repeatability tests and clinical trials. Compared with the prior art, the present invention extracts serotype 2 Riemerella anatipestifer lipopolysaccharide by hot phenol water method and coats the ELISA plate. By optimizing reaction conditions such as antigen coating conditions, dilution multiple and incubation conditions of serum to be tested / rabbit anti-duck enzyme-labeled antibodies, and substrate color development time, an indirect ELISA method for detecting serotype 2 Riemerella anatipestifer antibodies is successfully established.

The invention provides a CuCoNi-MOF aerogel nano-enzyme, a preparation method thereof and a detection reagent, and belongs to the technical field of antibody detection.The preparation method of the aerogel nano-enzyme comprises the following steps that bivalent copper salt, bivalent cobalt salt and bivalent nickel salt are mixed, then a reducing agent is added to reduce bivalent metal ions, then a dimethylimidazole solution is added, and the CuCoNi-MOF aerogel nano-enzyme is obtained. And reacting at 25-35 DEG C for at least 1 hour, finally taking out the precipitate after the reaction, washing with deionized water, and freeze-drying to obtain the target product. The detection reagent provided by the invention is prepared from the aerogel nano-enzyme as a raw material. The aerogel nano enzyme has high activity and strong stability, and can form a detection reagent with stable properties with a protein biomarker, and meanwhile, the preparation method is simple and convenient, and does not need expensive instruments, so that the manufacturing cost can be reduced. The detection reagent provided by the invention has very high sensitivity and accuracy.

The invention relates to an antibody detection kit for detecting chronic inflammatory demyelinating multiple nerve root neuropathy and a preparation method of the antibody detection kit. The antibody detection kit for detecting the chronic inflammatory demyelinating multiple nerve root neuropathy comprises an IgG antibody detection strip, an IgM antibody detection strip, a working solution and an auxiliary agent. The antibody detection kit disclosed by the invention can be used for simultaneously detecting nine autoantibodies related to the chronic inflammatory demyelinating multiple nerve root neuropathy, wherein the nine autoantibodies comprise NF155, NF186, CNTN1, CNTN2, CASPR1, CASPR2, GLIOMEDIN, NRCAM and MAG. The design of simultaneous detection of multiple antigens greatly improves the comprehensiveness of detection, so that multiple possible pathogenic factors can be covered in single detection, and the problem of missed diagnosis caused by single antibody detection is avoided.

The invention relates to a layered prediction method and system for the risk of malignant tumors related to dermatomyositis. The method comprises the following steps: collecting clinical index data of a patient suffering from dermatomyositis, the clinical index data comprising an anti-TIF1-gamma antibody detection result, an interstitial lung disease existence state, a dermatomyosis existence state, an anemia state and a dermatomyositis type; constructing a comprehensive scoring model to generate a risk stratification prediction result according to the clinical index data; the comprehensive scoring model is used for performing binary assignment on each index to obtain a score of a corresponding item; calculating the sum of scores of all indexes of the patient to obtain a total risk score; and layering the risk of the malignant tumor accompanied by the patient based on the total risk score, and outputting a risk layering result. According to the method, the cancer risk of the patient with dermatomyositis can be effectively predicted, and the reliability, convenience and practicability of layered prediction of the cancer risk are improved.

The invention discloses an anti-soluble transferrin receptor monoclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of antibody detection. According to the antibody, an L101-F760 amino acid sequence of human TfR protein is used as an immunogen, specific screening of B cells, reverse RNA (Ribonucleic Acid) into cDNA (Complementary Deoxyribose Nucleic Acid) through RT-PCR (Reverse Transcription-Polymerase Chain Reaction), then homologous recombination is performed to construct heavy and light chain vectors, and finally multiple rounds of screening are performed to obtain the purified sTfR monoclonal antibody, so that the sTfR protein can be specifically recognized, and the antibody has the advantages of high specificity and high sensitivity and can be widely applied to the field of immunotherapy. The natural sTfR protein in human serum can be recognized. The kit is applied to the detection and screening fields of immunohistochemistry, immunofluorescence chemistry, western blot, co-immunoprecipitation, indirect ELISA, flow cytometry and the like, especially has low background and no interference of non-specific binding impure protein during immunohistochemistry detection, can obtain more accurate detection and evaluation results, avoids interference of false positive and false negative, and has high detection accuracy. The method has great application value in the aspects of basic scientific research and clinical pathology detection.